AUPH - Dividend announcements

WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE, OTCQB:KNBIF) (the "Company", "Kane" or "Kane Biotech") announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the "Meeting") to consider the election of Dr. Robert Huizinga as an additional director of the Company. The information circular and other materials with respect to the Meeting will be filed on SEDAR+ by the Company in due course. Dr. Huizinga is currently the principal of Reformation Consulting Services. He was formerly the Executive Vice-President of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) and led the clinical development of voclosporin which had

Highlights Egregious Compensation Awarded to Executives Despite Poor Performance, Including ~$26 Million in Payouts to CEO Peter Greenleaf From 2019 – 2022 Calls on the Board to Heed Shareholder Feedback by Publicly Committing to a Strategic Review Process Believes a Sale to a Well-Capitalized Acquirer Could Yield up to $28 Per Share, or a More Than 192% Premium for Shareholders, Based on Recent Comparable Transactions Plans to Withhold Support for Chairman Dr. George Milne, CEO Peter Greenleaf and Compensation Committee Chair Joseph Hagan, Who Should All Be Held Accountable for Perpetuating a Culture of Self-Enrichment at the Expense of Aurinia Shareholders MKT Capital Ltd., a sign